Merz concludes enrolment in Phase III Xeomin trials for migraine

Phase 3XeominPositive

AI Analysis

Summary

Merz Therapeutics has completed patient enrolment in MINT-C and MINT-E, two global Phase III trials evaluating Xeomin for preventing migraine in adults.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Patient enrolment concluded in MINT-C and MINT-E Phase III trials

Importance:4/10

Sentiment:

0.30

migraineenrollment completionPhase 3botulinum toxinneurology

Related Companies

$GBCMD $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on October 16, 2026 8:14 AM

Read Original